- Home
- ELEV
as 11-21-2024 2:33pm EST
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 34.0M | IPO Year: | 2021 |
| Target Price: | $7.80 | AVG Volume (30 days): | 686.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.44 - $5.83 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Elevation Oncology Inc. Common stock News
ELEV Breaking Stock News: Dive into ELEV Ticker-Specific Updates for Smart Investing
PR Newswire
15 days ago
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
Zacks
a month ago
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock
GuruFocus.com
a month ago
Empery Asset Management's Strategic Acquisition in Elevation Oncology
PR Newswire
2 months ago
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
PR Newswire
3 months ago
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Clinical Trials Arena
3 months ago
Elevation Oncology reports data from Phase I trial of EO-3021 for solid tumours
PR Newswire
3 months ago
Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
PR Newswire
3 months ago
Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2
Compare ELEV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELEV Elevation Oncology Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.